25I-NBMD
25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor with a Ki of 0.049nM at the human 5HT2A receptor. The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT2A receptor.
primaryTopic
25I-NBMD
25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor with a Ki of 0.049nM at the human 5HT2A receptor. The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT2A receptor.
has abstract
25I-NBMD (NBMD-2C-I, Cimbi-29) ...... shape of the 5-HT2A receptor.
@en
CAS number
919797-25-4
FDA UNII code
R99110126K
IUPAC name
N-[(2H-1,3-benzodioxol-4-yl)methyl]-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine
@en
PubChem
thumbnail
Wikipage page ID
22,858,337
Wikipage revision ID
736,517,558
ChemSpiderID
26,234,932
legal UK
molecular weight
4.41259e+2
smiles
c13OCOc3cccc1CNCCccc2OC
StdInChIKey
NJNMIPDEUMTYNV-UHFFFAOYSA-N
Verifiedfields
verifiedrevid
452,164,662
subject
hypernym
comment
25I-NBMD (NBMD-2C-I, Cimbi-29) ...... shape of the 5-HT2A receptor.
@en
label
25I-NBMD
@en
